Journal article
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
Abstract
IntroductionEfficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1.MethodsExploratory analyses of all primary and secondary endpoints (non-responder imputation and as observed for binary endpoints; mixed-effect model repeated measures and as observed for continuous endpoints), and …
Authors
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R
Journal
Rheumatology and Therapy, Vol. 10, No. 1, pp. 275–292
Publisher
Springer Nature
Publication Date
2 2023
DOI
10.1007/s40744-022-00499-w
ISSN
2198-6576